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Proteases are involved in the pathogenesis of inflam-
matory diseases by participating in the activation of
mediator systems and by producing proteolytic tis-
sue injury. Homeostatic control of inflammation
is accomplished in part by physiologic protease
inhibitors. The authors investigated the effective-
ness of a number of synthetic protease inhibitors
in ameliorating the glomerular injury induced by
immune complex-mediated glomerulonephritis
in mice. Two amidine-type protease inhibitors, bis
(5-amidino-2-benzimidazolyl)methane and 1,2-bis
(5-amidino-2-benzimidazolyl)ethane, had the greatest
PROTEOLYTIC enzymes influence or control a
large variety of humoral and cellular reactions of the
body. They are prominently involved in the activa-
tion ofinflammatory mediator systems by participat-
ing in such multistep pathways as complement acti-
vation, Hageman factor-dependent kinin generation,
coagulation, and fibrinolysis."2 Upon release from
leukocytes, proteases can also be direct effectors of
tissue injury.
Recognition of this importance of proteolysis in
many pathophysiologic processes has prompted in-
terest in exogenous and endogenous protease inhibi-
tors as anti-inflammatory agents. Physiologic (endog-
enous) protease inhibitors, such as a1-proteinase
inhibitor (a, -antitrypsin) and a2-macroglobulin, play
a homeostatic role in counteracting proteolytic pro-
cesses, including inflammation. At sites ofinflamma-
tion, mediator and effector proteolytic events are
dominant over antiproteolytic control mechanisms.
It might be possible to regain anti-inflammatory con-
trol by the administration of supplementary exoge-
nous antiproteases, such as synthetic protease inhibi-
tors. To test this hypothesis, we chose to study the
effects offour synthetic protease inhibitors on murine
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effects. They caused a marked reduction in glomerular
necrosis (P < 0.001) but did not affect the amount or
site ofimmune complex localization or leukocyte in-
flux. The inhibition constants ofthe protease inhibitors
against nine purified physiologic proteases were deter-
mined. These results were discussed in relation to the
effectiveness ofthe protease inhibitors in reducing glo-
merular injury. This investigation indicates that the
administration of synthetic protease inhibitors can
have a beneficial effect on immune-mediated inflam-
matory injury. (AmJ Pathol 1987, 127:499-506)
immune complex-induced glomerulonephritis.3 We
selected three synthetic amidino compounds with a
wide inhibitory spectrum against trypsinlike pro-
teases and a rather specific inhibitor of complement.
Materials and Methods
Experimental Animals and Protease Inhibitor Doses
One hundred twenty-one 16-18-week-old male
BALB/c mice (Charles River Breeding Laboratories)
were divided among 9 different experimental groups
(Table 1). Ninety mice (Groups I-VI) received daily
intraperitoneal injections of4 mg of horse apoferritin
(HAF) (Sigma Chemical Co.) for 12 days. On Days
7-12, Group 1 (30 mice) received intraperitoneal in-
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Table 1 -Experimental Groups
Number HAF Days to Protease










30 4 13 none
20 4 13 BABIM
(20 mg/kg/day)
10 4 13 BABIM
(5 mg/kg/day)
10 4 13 BABIE
10 4 13 K-76 COONa
10 4 13 ABI
12 0 13 BABIM
9 4 33 BABIM
10 4 33 None
*BABIM, bis (5-amidino-2-benzimidazolyl)methane; BABIE, 1,2-bis(5-
amidino-2-benzimidazolyl )ethane; K-76 COONa, 6,7-dihydroxy-2,5,5,8a-
tetramethyl,1 ,2,3,4,4a,5,6,7,8,8a-decahydronaphthalene-1 -spiro-2'- (7'car-
boxyl-6'-formyl-4'-hydroxy-2',3'-dihydrobenzofuran); ABI, 1 -4-amidino-
benzyl)indole.
jections of 0.1 ml phosphate-buffered saline (PBS),
and Groups II-VI received daily intraperitoneal
injections of synthetic protease inhibitors in 0.1
ml PBS. The protease inhibitors used were bis(5-
amidino-2-benzimidazolyl)methane (BABIM); 1,2-
bis(5-amidino-2-benzimidazolyl)ethane (BABIE);
1-(4-amidinobenzyl)indole (ABI); and 6,7-dihy-
droxy-2,5, 5,8a-tetramethyl, 1, 1,2,3,4,4a,5,6, 7,8,8a-
decahydronaphthalene -1- spiro - 2'- (7'carboxyl - 6'-
formyl-4'-hydroxy-2',3'-dihydrobenzofuran) (K-76
COONa). The three amidines were synthesized ac-
cording to previously described methods.4'5 K-76
COONa was obtained from W. Miyazaki and Otsuka
Pharmaceutical Co. (Rockville, Md).6'7
The protease inhibitor daily dose was 20 mg/kg in
all groups except Group III, which received 5 mg/kg.
Group VII contained 12 mice, which received 13
daily injection of PBS but no HAF. On Days 7-12,
half of this group received 5 mg/kg/day BABIM and
half 20 mg/kg/day BABIM.
On Day 13, all mice in Groups I-VII were anesthe-
tized with ether, blood was obtained from the retroor-
bital venous plexus, and the animals were killed by
cervical dislocation. Kidney tissue was processed for
light, immunofluorescence, and transmission elec-
tron microscopy by previously reported methods.3
For direct immunofluorescence microscopy, we im-
munostained 4-,u frozen sections of kidney with fluo-
resceinated goat antibodies to mouse IgG, IgM, and
C3 and rhodaminated goat anti-HAF (Cappel Labo-
ratories, Inc., Cochranville, Pa).
To test the effect of BABIM on survival, 19 mice
(Groups VIII and IX) received 4 mg/kg/day intraper-
itoneal HAF for 32 days, or until death. On Days 7
through 32, Group VIII (9 mice) received 20 mg/kg
BABIM in 0.1 ml PBS, and Group IX (10 mice) re-
ceived PBS alone. On Day 33, mice that had not ex-
pired earlier were sacrificed and sampled as described
above.
Pathologic Analysis of Renal Lesions
Kidney tissue from all but 2 of the 121 mice was
evaluated by light microscopy. Two Group IX ani-
mals that died prior to sacrifice were unsuitable for
microscopic study. The overall severity of light-
microscopic abnormalities was subjectively quanti-
fied on a scale of 0 to 4+. No immunofluorescence
was designated by 0, 0.5+ indicated trace focal seg-
mental staining, and I + to 4+ indicated progressively
more intense and widespread staining from slight
(1+) to maximum (4+). The location of immuno-
staining, that is, mesangial and/or capillary wall, was
also recorded.
Immunofluorescence microscopy was carried out
on all animals except those in the survival study
(Groups VIII and IX). Mesangial and capillary wall
immunostaining of nonnecrotic glomeruli were each
quantified on a scale of 0 to 4+ (0, none; 4+, maxi-
mal). In animals that received HAF, nonnecrotic glo-
meruli had well-defined granular mesangial and cap-
illary wall immune deposits that outlined the normal
structure. In necrotic segments, the normal structure
was disrupted, which resulted in the localization of
immunoglobulins, complement, and HAF in a
smudged distribution. This corresponded to foci of
necrosis that by light microscopy had replacement of
the normal architecture by amorphous acidophilic
material, karyolysis, and karyorrhexis. For each ani-
mal, except those in Groups VIII and IX, the percent-
age of globally necrotic glomeruli was determined by
immunofluorescence microscopy. Because immuno-
fluorescence microscopy was not performed on renal
tissue from Groups VIII and IX, the percentage of
globally necrotic glomeruli in those mice was deter-
mined by light microscopy. The P values for glomer-
ular necrosis in the various experimental groups were
calculated using the Statistical Analysis software
package from Human Systems Dynamics on an
Apple Ile computer.
Transmission electron microscopy was carried out
on a minimum of 2 animals per group. Particular
attention was paid to the extent and location of glo-
merular electron-dense deposits and the characteris-
tics of glomerular inflammation.
Assay of Plasma Creatinine and
Anti-HAF Antibodies
By means ofa standard autoanalyzer method,8 cre-
atinine was quantitated in plasma from survivors in
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Groups VIII and IX and from 10 animals in Group I,
10 animals in Group II, and all animals ofGroup IV.
Plasma anti-HAF antibody activity was measured
in all animals by means ofan enzyme immunoassay.9
The wells of 96-well microtiter plates (Costar, Cam-
bridge, Mass) were filled with 0.1 mg/ml HAF in PBS.
The plates were left for 1 hour at room temperature,
and then overnight at 4 C. After three washes with
0.5% Tween-20 (Sigma) in PBS, the wells were filled
with 5% bovine serum albumin (Sigma) for 1 hour
and then washed with PBS. Mouse plasma samples
diluted in PBS were incubated in wells for 1 hour at
room temperature. After washing, wells were incu-
bated for 20 minutes with peroxidase-labeled goat
antibodies specific for mouse IgG, IgM, and light
chains (Tago, Inc. Burlingame, Calif), then washed. A
solution of 0.04% ortho-phenylendiamine dihy-
drochloride (Eastman Kodak, Rochester, NY) in pH
5.0 citrate phosphate buffer with 0.012% hydrogen
peroxide was added. After 20 minutes, the optical
density at 450 nm was determined by means of a
Titertek Multiscan (Flow Laboratories, Helsinki,
Finland). All samples were run in duplicate. Test sam-
ples were compared with standard pools of plasma
from control mice and hyperimmunized BALB/c
mice. Results are expressed as a percentage of the
value obtained for the concurrently analyzed stan-
dard hyperimmune pool.
Determination of Inhibition Constants (K; Values)
of Protease
The potency of the inhibitors against various puri-
fied proteases was determined from amidase or ester-
ase assays employing sensitive synthetic substrates.
The inhibition constants (Ki values) were obtained
graphically according to Dixon'0 by plotting the recip-
rocals ofthe initial reaction velocities at two different
substrate concentrations against different inhibitor
concentrations.
Incubations were carried out at 37 C with the ma-
jority of the enzymes, the only exceptions being the
Clr and Cls assays, which were run at 23 and 25 C,
respectively. The pH ofthe tests was 8.1 with trypsin,
thrombin, urokinase, plasma kallikrein, and pancre-
atic kallikrein. It was 8.3 with factor Xa, 7.6 with
plasmin, 7.5 with Cl r, and 8.0 with C I s. Details ofthe
assays for trypsin, factor Xa, thrombin, urokinase,
plasmin, and pancreatic kallikrein were reported pre-
viously."",12 The substrates used in those assays were
the following: for trypsin, thrombin, plasmin and
pancreatic kallikrein N-benzoyl-DL-arginine-p-ni-
troanilide HCI (Sigma); for factor Xa N-benzoyl-L-
isoleucyl-L-glutamyl-glycyl-L-arginine-p-nitroanilide
HCI (S-2222, Kabi Vitrum, Stockholm, Sweden),
and for urokinase L-pyroglutamyl-glycyl-L-arginine-
p-nitroanilide HCI (S-2444, Kabi Vitrum).
Plasma kallikrein assays contained 1.3 X 10-3
plasma equivalence units of the enzyme per milliliter
of 0.05 M Tris-HCl buffer. Hydrolysis of the sub-
strate H-D-prolyl-L-phenylalanyl-L-arginine-p-nitro-
anilide HCI (S-2302, Kabi Vitrum)13 was followed
colorimetrically at 410 nm, as with all other nitroani-
lides.
For the evaluation of Cls, the protease (1.1 nM)
was incubated in 0.038 M Tris-HCl buffer containing
150,uM 5,5'-dithio-bis(2-nitrobenzoic acid) (DTNB,
Ellman's reagent),'4 1 mM NaCl, 10,uM EDTA, 1%
(vol/vol) DMF, 100,uM KH2PO4,400,uM Na2HPO4,
and the substrate thiobenzyl benzyloxycarbonyl-L-
lysinate (Peninsula Laboratories).'5 The reaction was
monitored by the color development at 412 nm which
results from the chromogenic attack on DTNB by the
mercaptan released.
The assay for Cl r was based on the same principles
as the one for C I s, ie, on hydrolysis ofa thioester. The
reaction mixture contained 25.2 nM ClS, 0.05 M
Tris-HCI, 650 ,uM DTNB, 750 ,uM NaCl, 5 ,uM
EDTA, 0.5% (vol/vol) DMF, 50 ,uM KH2PO2, 200
,iM Na2HPO4, and the substrate benzyloxycarbonyl-
glycyl-L-arginine thioisobutyl ester HCI (Enzyme
Products). 16
Trypsin (bovine, crystallized) was obtained from
Worthington Biochemical Corporation. Human Fac-
tor Xa was a product ofDiagnostic Reagents, Thame,
Oxon, England. Thrombin (bovine, topical) was pur-
chased from Parke, Davis and Company. High-
molecular-weight human urokinase was contributed
as Winkinase by Winthrop Laboratories. Human
plasmin and human plasma kallikrein were bought
from Kabi Vitrum. Porcine pancreatic kallikrein was
a gift ofFarbenfabriken Bayer AG, Wuppertal-Elber-
feld, West Germany. Highly purified preparations of
C I r and C I s were obtained by a previously published
procedure. 17
Complement Hemolytic Assay
The total hemolytic complement activity of serum
from mice given K-76 COONa (Group V) and ABI
(Group VI) was determined by means of a modified
standard CH50 assay. Sheep red blood cells were sensi-
tized (EA) with a 1: 75 dilution ofanti-sheep hemoly-
sin (Difco Laboratory, Detroit, Mich), and washed in
cold gelatin veronal buffered saline. Mouse blood was
harvested from the retroorbital plexus and clotted at
room temperature. After separation of serum from
clot, the serum was immediately placed on ice and
Vol. 127 * No. 3
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evaluated by CH50 during the same day. Serum was
added to EA 30 minutes after hemolysin had been
added. Hemolysis was measured spectrophotometri-
cally.
Results
All animals that received HAF developed diffuse
proliferative glomerulonephritis. This glomerulone-
phritis had the pathologic features previously de-
scribed by us in BALB/c mice given HAF.3 Ofthe 1 19
mice examined by light microscopy, all had severe
glomerular injury except for the 12 mice in Group
VII, which had no lesions. In mice that received HAF,
glomeruli were either markedly hypercellular (Figure
1) or had segmental to global necrosis (Figure 2). In
nonnecrotic glomeruli, the degree of glomerular hy-
percellularity was not significantly different between
the experimental groups. The degree of glomerular
necrosis, however, did vary among the experimental
groups. Glomerular necrosis was very apparent by
immunofluorescence microscopy, producing a
smudged appearance in the glomeruli (Figure 3),
compared with the discrete granular immune de-
posits seen in nonnecrotic glomeruli (Figure 4). There
Figure 2-Extensive necrosis with loss of nuclei in a glomerulus from a
Group mouse that received HAF for 12 days and no protease inhibitor.
(H&E, X900)
Figure 1-Marked hypercellularity in a glomerulus from a Group II mouse
that received HAF for 12 days and 20 mg/kg BABIM for 6 days. (H&E, X900)
Figure 3-Smudged staining shown by immunofluorscence microscopy in
two glomeruli from a Group mouse that received HAF for 12 days and no
protease inhibitor. (Anti-mouse IgG, X600)
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Table 2-Protease Inhibitor Effects on Glomerular Necrosis,
Glomerular Immune Complex Localization, and Plasma Anti-HAF













Figure 4-Granular, predominantly mesangial staining by immunofluores-
cence microscopy in two glomeruli from a Group II mouse that received HAF
for 12 days and 20 mg/kg BABIM for 6 days. (Anti-mouse IgG, X600)
were no discernable ultrastructural differences in
nonnecrotic glomeruli between control mice given
HAF and no protease inhibitor and mice given HAF
and an inhibitor. All nonnecrotic glomeruli had large
global mesangial electron-dense deposits and scat-
tered small subepithelial and subendothelial dense
deposits. All glomeruli had hypercellularity with
mononuclear and polymorphonuclear leukocytes.
Necrotic glomeruli had large masses of amorphous
moderately electron-dense material, cellular debris,
and reduced intact cells.
Short-Term (13-Day) Experiment
As shown in Table 2, of the mice that received 12
days of HAF (Groups I-VI), those that received no
protease inhibitor had the greatest percentage ofglob-
ally necrotic glomeruli (47.5%). There was a striking
and statistically highly significant reduction in ne-
crosis in mice that had been given 20 mg/kg/day
BABIM, 5 mg/kg/day BABIM, or 5 mg/kg/day
BABIE. The other two inhibitors studied (K-76
COONa and ABI) were much less effective than either
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of mesangial immunofluorescence in nonnecrotic
ferences with respect to the inhibitor-free controls
were not statistically significant.
By immunofluorescence microscopy, there was no
difference among Groups I-VI mice with respect to
the distribution or intensity of immunostaining for
IgG, IgM, C3, or HAF in nonnecrotic glomeruli. Glo-
merular immunostaining was most intense in mesan-
gial regions, but almost all glomeruli had a minor
degree ofcapillary wall staining for IgG, C3, and HAF
(Figure 4). Plasma levels of anti-HAF antibodies did
not differ among the groups of mice that received
HAF.
Plasma creatinine was measured in 10 mice from
Groups I (no protease inhibitor), II (BABIM), and IV
(BABIE). The mean creatinine was 30.1 ,umol/l in
Group I, 23.9,umol/I in Group II, and 27.4,umol/1 in
Group IV. Only the difference between Groups I and
II was statistically significant (P = 0.005).
Group VII mice that received BABIM but no HAF
had no glomerular lesions by light or electron micros-
copy, only low intensity glomerular immunoglobulin
immunostaining, no glomerular HAF immunostain-
ing, and a plasma anti-HAF antibody assay activity
of only 13.4% (± 5.5 SD). Age-matched normal
BALB/c mice had a mean anti-HAF activity of 9.5%
(± 1.9 SD).
Long-Term (33-Day) Survival Experiment
In mice that received HAF for 32 days or until
death caused by renal failure, 7 of 10 that did not
receive BABIM died within 33 days, whereas only 3 of
9 died that had received 20 mg/kg/day BABIM. Ofthe
19 mice in groups VIII and IX, 17 were examined by
light microscopy. All of these mice had proliferative
glomerulonephritis. There was no difference in the
Vol. 127 * No. 3
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degree of hypercellularity in non-necrotic glomeruli
between mice that received BABIM and those that did
not.
There was, however, a marked difference in the
extent of necrosis. Mice that received BABIM (Group
VIII) had on average 8.4% globally necrotic glomer-
uli, compared with 33.1% in mice not receiving
BABIM (Group IX). In either group, the amount of
necrosis was different between those mice that died
prior to 33 days, compared with those sacrificed at 33
days. In Group VIII (BABIM-treated), mice dying
prior to 33 days had 16.7% necrotic glomeruli and
those sacrificed at 33 days had 4.3%. In Group IX,
those dying early had 44.0% necrotic glomeruli, com-
pared with 15.0% in sacrificed mice.
Plasma creatinine level and anti-HAF activity were
measured in the 6 Group VIII and 3 Group IX mice
that survived for 33 days. There was no difference in
anti-HAF antibody activity between the two groups.
Plasma creatinine was not significantly different;
however, the groups of mice evaluated were small.
Group VIII mice had a mean serum creatinine level of
32.7 ,umol/l, and Group IX had 36.2 ,umol/l.
Complement Hemolytic Activity
The dose of K-76 COONa administered to each
mouse was based on two factors. First the concentra-
tion of K-76 COONa was determined that was re-
quired to inhibit in vitro 95% of the lysis of sensitized
sheep red blood cell (SRBCs) by mouse serum. This
concentration was then used to calculate the in vivo
dose. Second, the administered dose was equivalent
to that reported as effective in other systems.7 Total
hemolytic activity of serum from experimental ani-
mals that received K-76 COONa (Group V), how-
ever, was no different from that of control mouse
serum.
The total hemolytic activity of serum taken from
mice that received ABI (Group VI) also was no differ-
ent from that ofcontrol serum. The serum concentra-
tion ofABI used in Group VI inhibited in vitro 38% of
SRBC lysis, compared with control serum. When the
serum concentration ofABI in mice was increased to
be equivalent to 95% inhibition ofSRBC lysis in vitro,
all mice died within 24 hours.
Inhibition Constants of Protease Inhibitors
Table 3 gives the inhibition constants of BABIM,
BABIE, and ABI with nine trypsinlike proteases. Not
included in the table is the only non-amidino com-
pound studied, K-76 COONa. At concentrations of
up to 1 X 14-4 M it did not produce any inhibition of
the proteases tested.
Table 3-Inhibition Constants (K1 Values) of BABIM, BABIE,









































166.0 ± 90.5 31.4 + 5.44
*Values are means ± SD (n = 3, except in the case of Cl , where values






These studies indicate that the systemic administra-
tion of certain protease inhibitors can alter the mor-
phologic characteristics of immune complex-me-
diated glomerulonephritis in mice. Some of the
synthetic protease inhibitors tested effected a striking
reduction in the extent of glomerular necrosis while
not changing at all the glomerular influx of leuko-
cytes, site or amount ofglomerular immune complex
localization, or magnitude ofanti-HAF antibody pro-
duction.
The protease inhibitors having the greatest effects
on glomerular injury, BABIM and BABIE, produced
a 69-89% reduction in the number ofglomeruli with
global necrosis. Because glomerular complement lo-
calization and leukocyte influx were not reduced, it is
most likely that the protease inhibitors produced their
effects by inactivating or preventing the release of
leukocyte lytic proteases.
The glomerular filtration rate, as evidenced by
plasma creatinine levels, was only modestly improved
in mice given BABIM. This is not surprising in view of
the inability of the protease inhibitors used in these
experiments to prevent components of glomerular
inflammation other than necrosis. This also is most
likely the basis for the more impressive reduction in
necrosis than in mortality. The reduction ofglomeru-
lar necrosis produced by protease inhibitors, how-
ever, did correlate with improved survival. In mice
given HAF for 32 days or until death caused by renal
failure, 70% not given BABIM died, compared with
33% given BABIM. In each treatment group, mice
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that died had more necrosis than mice that survived.
In mice that did not receive BABIM, those that died
had an average of 44% globally necrotic glomeruli,
compared with 15% in those that survived. In mice
given BABIM, those that died had 17% necrosis and
those that survived had 4% necrosis.
The most plausible explanation for the beneficial
influence of the amidine-type inhibitors is that they
interfered with the damaging action of proteases in
the glomeruli. The specificity requirements of the in-
hibitors allow us to narrow the search for the pro-
tease(s) involved to those with activity against arginyl
or lysyl bonds, ie, with trypsinlike characteristics.
Even with those restrictions, however, there still re-
mains a long list of proteases that have to be consid-
ered. It would include intracellular as well as humoral
enzymes. To begin, factor XIIa and plasma kallikrein
may both be implicated. They are normally present in
plasma in the zymogen form, but they can be acti-
vated at the site of endothelial cell injury in the glo-
meruli and may, in turn, stimulate degranulation of
neutrophils.19'20 Among others, elastase, collagenase,
and plasminogen activator would be secreted with the
granules20-24 and would be in a position to promote
tissue necrosis. Additional amounts of the three pro-
teases could be recruited from stimulated macro-
phages accumulating in the glomeruli.2527 Freshly re-
leased collagenase is probably initially present as the
zymogen but can be fully activated by plasma kal-
likrein or plasmin.28'29 Factor XIIa, kallikrein, plas-
minogen activator, and plasmin would all be suscepti-
ble to inhibition by amidines. Once active, however,
neither collagenase nor elastase would be affected. It
should be noted that all proteases in the clotting cas-
cade except factor XIIa are trypsinlike and can be
expected to be blocked by amidino compounds. The
same holds true for the early components of the clas-
sical pathway of complement activation, ie, Cl r and
Cls.
In an attempt to correlate the necrosis-preventing
activity of the three amidines selected with their abil-
ity to inhibit one or more well-defined proteases, the
inhibition constants (Ki values) were obtained for
nine likely target enzymes (Table 3). In addition to
trypsin, two clotting factors (Factor Xa and throm-
bin), two fibrinolytic agents (plasmin and urokinase),
two members ofthe kinin generating system (pancre-
atic and plasma kallikrein), and two components of
the complement system (Clr and Cl S) were exam-
ined. As BABIM and BABIE were much more effec-
tive than ABI in the prevention of glomerular ne-
crosis, any protease considered a candidate for the
mediator of necrosis would have to show significantly
lower Ki values with BABIM and BABIE than with
ABI. From the data in Table 3 it is evident that no
protease fulfilled these conditions, except possibly
Factor Xa. One might speculate that prevention of
thrombosis in glomerular capillaries by the blockage
of Factor Xa could have reduced the glomerular in-
jury.
ABI is an inhibitor of C Ir and C I s (Table 3), and
K-76 COONa is an inhibitor of C5.30 At the doses
used in this investigation, however, no reduction in
blood hemolytic complement activity was produced.
Therefore, the ABI and K-76 COONa data neither
support nor rule out a role for complement inhibition
in reducing necrosis.
Complement inhibition at any step would not ex-
plain the antinecrosis activity of BABIM. Besides
being only a very weak inhibitor of purified Cl r and
Cls (Table 3), BABIM had no effect on guinea pig
complement-induced hemolysis, even at a concentra-
tion of 1 X l0-4 M (data not shown).
The amelioration of experimental immune com-
plex-mediated glomerulonephritis by amidines is fur-
ther evidence for the role ofproteases in the induction
of immune-mediated inflammation. This anti-in-
flammatory role for protease inhibitors also is sup-
ported by the reports of patients with a congenital
deficiency of oa,-antitrypsin who develop glomerulo-
nephritis and necrotizing arteritis.31'32 The usefulness
of synthetic protease inhibitors in the treatment of
another type of experimental glomerulonephritis has
been reported by Ikehara et al.33 They showed that the
immune complex-mediated "lupus" glomerulone-
phritis that develops spontaneously in NZB/NZW F1
mice can be reduced in severity by the administration
of FUT- 175 (6-amidino-2-naphthyl p-guanidino-
benzoate dimethanesulphonate). As in our study,
they observed no major change in immune deposits.
There was, however, a reduction in glomerular injury
and an improvement in renal function.
Protease inhibitors are of potential value in study-
ing pathogenic mechanisms of inflammation and as
antiinflammatory pharmacologic agents.
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